Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, in collaboration with the University of California, San Francisco (UCSF), today announced Nature Medicine has published its study demonstrating the clinical utility of mNGS testing to identify difficult-to-detect pathogens among adults and children with serious central nervous system infections. Soon to be widely available through the company’s Delve Detect testing service, the study showed mNGS testing is more sensitive than direct-detection testing.
Delve was founded by UCSF professors Charles Chiu, Joe DeRisi, and Michael Wilson.